Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer

References

• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London, England). 2014;383(9935):2168–2179.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Schweitzer N, Vogel A. Systemic therapy of cholangiocarcinoma: from chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol. 2015;29(2):345–353.
   PubMed Web of Science ®Google Scholar
• Wiedmann MW, Mössner J. Molecular targeted therapy of biliary tract cancer–results of the first clinical studies. Curr Drug Targets. 2010;11(7):834–850.
   PubMed Web of Science ®Google Scholar
• Putra J, de Abreu FB, Peterson JD, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol. 2015;99(2):240–244.
   PubMed Web of Science ®Google Scholar
• Merla A, Liu KG, Rajdev L. Targeted therapy in biliary tract cancers. Curr Treat Options Oncol. 2015;16(10):48.
   PubMed Web of Science ®Google Scholar
• Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci. 2012;19(4):326–336.
   PubMed Web of Science ®Google Scholar
• Marino D, Leone F, Cavalloni G, et al. Biliary tract carcinomas: from chemotherapy to targeted therapy. Crit Rev Oncol Hematol. 2013;85(2):136–148.
   PubMed Web of Science ®Google Scholar
• Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992;4(1):1–24.
   PubMedGoogle Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–1966.
   PubMed Web of Science ®Google Scholar
• PUBMED [Internet]. [cited 2015 Nov 7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed.
   Google Scholar
• Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57(21):4838–4848.
   PubMed Web of Science ®Google Scholar
• Tarceva summary of product characteristics [Internet]. EMA. [cited 2015 Nov 7]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf.
   Google Scholar
• TARCEVA full prescribing information [Internet]. FDA. [cited 2015 Nov 7]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.
   Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016 Jan;27(1):134–140.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang Q-D, Li Z-H, et al. Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis. World J Gastroenterol. 2014;20(47):18001–18012.
   PubMed Web of Science ®Google Scholar
• Brieau B, Dahan L, De Rycke Y, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121(18):3290–3297.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Hubner RA, David Ryder W, et al. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–2338.
   PubMed Web of Science ®Google Scholar
• Jensen LH, Jakobsen A. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. Expert Rev Anticancer Ther. 2011;11(4):589–600.
   PubMed Web of Science ®Google Scholar
• Wiedmann M, Feisthammel J, Blüthner T, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs. 2006;17(7):783–795.
   PubMed Web of Science ®Google Scholar
• Jimeno A, Rubio-Viqueira B, Amador ML, et al. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol Cancer Ther. 2007;6(3):1079–1088.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.
   PubMed Web of Science ®Google Scholar
• Mody K, Strauss E, Lincer R, et al. Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report. BMC Cancer. 2010;10:570.
   PubMed Web of Science ®Google Scholar
• Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.
   PubMed Web of Science ®Google Scholar
• Rogers JE, Law L, Nguyen VD, et al. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014;5(6):408–413.
   PubMedGoogle Scholar
• Dragovich T, Huberman M, Von Hoff DD, et al. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2007;60(2):295–303.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Porter JM, Foster AE, et al. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res. 2008;14(4):1131–1137.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–3074.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558.
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Ramasubbaiah R, Yu M, et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: hoosier oncology group GI06-101. Oncologist. 2012;17(1):13–e23.
   PubMed Web of Science ®Google Scholar
• Quintela-Fandino M, Le Tourneau C, Duran I, et al. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther. 2010;9(3):751–760.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Rankin C, Siegel AB, et al. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014;110(4):882–887.
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol. 2010;28(21):3491–3497.
   PubMed Web of Science ®Google Scholar
• Rohrberg KS, Olesen RK, Pfeiffer P, et al. Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. Acta Oncol (Madr). 2012;51(2):234–242.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–188.
   PubMed Web of Science ®Google Scholar
• Kim ST, Jang K-T, Lee J, et al. Molecular subgroup analysis of clinical outcomes in a phase 3 study of gemcitabine and oxaliplatin with or without erlotinib in advanced biliary tract cancer. Transl Oncol. 2015;8(1):40–46.
   PubMed Web of Science ®Google Scholar
• Kim ST, Jang K-T, Lee SJ, et al. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer. 2015;15(1):530.
   PubMed Web of Science ®Google Scholar
• Choi MK, Choi JY, Lee J, et al. Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib. Med Oncol. 2014;31(7):23.
   PubMed Web of Science ®Google Scholar
• Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013;369(5):397–400.
   PubMed Web of Science ®Google Scholar
• Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. Am J Prev Med. 1999;17(4):285–294.
   PubMed Web of Science ®Google Scholar
• The Lancet Oncology. Quality and value in cancer care. Lancet Oncol. 2013;14(3):177.
   PubMedGoogle Scholar
• Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med. 2007;146(12):848–856.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277–1280.
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547–1573.
   PubMed Web of Science ®Google Scholar
• Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1225–1236.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20(6):1698–1705.
   PubMed Web of Science ®Google Scholar
• Sorensen BS, Wu L, Wei W, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014;120(24):3896–3901.
   PubMed Web of Science ®Google Scholar
• Willyard C. ‘Basket studies’ will hold intricate data for cancer drug approvals. Nat Med. 2013;19(6):655.
   PubMed Web of Science ®Google Scholar
• Menis J, Hasan B, Besse B. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur Respir Rev. 2014;23(133):367–378.
   PubMedGoogle Scholar